Visterra is a biologics research and early-stage clinical development company based in Cambridge, MA, dedicated to developing therapies for patients with immune-mediated and hard-to-treat diseases. Their innovative approach combines cutting-edge computational, AI, and experimental research methods with agile preclinical development and creative trial designs.
With a vision focused on making a meaningful impact, Visterra fosters a culture of innovation, teamwork, and perseverance, empowering employees to collaborate in a high-performing, agile team environment. Their lead program, Sibeprenlimab VIS649, is an investigational humanized IgG2 monoclonal antibody aimed at treating IgA nephropathy, a chronic kidney disease.
Generated from the website